(Q40775925)

English

Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite

scientific article published in March 2000

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

author name string

Nienaber V

1

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Wang J

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Davidson D

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Henkin J

4

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

language of work or name

0 references

publication date

1 March 2000

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Journal of Biological Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

275

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

7239-7248

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

The crystal structure of the catalytic domain of human urokinase-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Invasion and metastasis: Biology and clinical potential

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Crystal structures of matrilysin-inhibitor complexes

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Structure-based drug design: progress, results and challenges

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Amiloride selectively inhibits the urokinase-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Structure and function of microplasminogen: I. Methionine shuffling, chemical proteolysis, and proenzyme activation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Inhibition of serine proteinases by p-carbethoxyphenyl esters of epsilon-guanidino- and epsilon-amino caproic acid: thermodynamic and molecular modeling study

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Processing of X-ray diffraction data collected in oscillation mode

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

AMoRe: an automated package for molecular replacement

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Structure of human des(1-45) factor Xa at 2.2 A resolution

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

The refined crystal structure of bovine beta-trypsin at 1.8 A resolution. II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7.0

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Protein engineering as a tool for crystallography.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Thrombin active site inhibitors

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Tumor-associated urokinase-type plasminogen activator: biological and clinical significance

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

The synthesis of three 4-substituted benzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Urinary and kidney cell plasminogen activator (urokinase)

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Structure of crystalline alpha-chymotrypsin. IV. The structure of indoleacryloyl-alpha-chyotrypsin and its relevance to the hydrolytic mechanism of the enzyme

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Pharmacological effects in animals and normal human subjects of the diuretic amiloride hydrochloride (MK-870>

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Structure of crystalline alpha-chymotrypsin. 3. Crystallographic studies of substrates and inhibitors bound to the active site of alpha-chymotrypsin

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

An x-ray diffraction study of inhibited derivatives of alpha-chymotrypsin

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Structure of crystalline -chymotrypsin. V. The atomic structure of tosyl- -chymotrypsin at 2 A resolution

1 reference

https://api.crossref.org/works/10.1074%2FJBC.275.10.7239

21 January 2018

Identifiers

10.1074/JBC.275.10.7239

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

release_rzwzhjbnzbblzpjrtold3qfnba

1 reference

https://api.fatcat.wiki/v0/release/rzwzhjbnzbblzpjrtold3qfnba

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40775925&oldid=1906980202"